Join our community of smart investors

Vectura improves profit guidance

The respiratory drug developer says cash profits will exceed expectations this year
January 3, 2019

We kept the faith when respiratory specialist Vectura (VEC) announced a Phase III drug failure at the end of November, so the 10 per cent jump in the share price on the back of raised profit guidance feels like a just reward.

IC TIP: Buy at 80p
This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in